QTORIN rapamycin 3.9 percent gel

Name: QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Current treatment options and standard of care
Published: 2026-09-14T15:39:06-04:00

Microcystic lymphatic malformations

Manufacturer: Palvella Therapeutics
Regulatory submission: NDA submitted August 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

21 evidence topics · 23 sources

Conservative and supportive care1 evidence topic · 4 sources
Sclerotherapy1 evidence topic · 1 source
Surgical resection1 evidence topic · 1 source
Electrocoagulation1 evidence topic · 1 source
Laser therapy1 evidence topic · 1 source
Radiofrequency ablation1 evidence topic · 1 source
Topical mTOR inhibitors7 evidence topics · 16 sources
Systemic mTOR inhibitors2 evidence topics · 2 sources
Kampo herbal formulas1 evidence topic · 1 source
Limitations of current therapies5 evidence topics · 3 sources

QTORIN rapamycin 3.9 percent gel

Current treatment options and standard of care

Compression therapy and lymphatic drainage

PI3K inhibitors